Skip to main content

Media Category: Diagnosis

Jelena Drulović : Building Regional Expertise and Knowledge Exchange in Multiple Sclerosis

In this short video interview, Jelena Drulović explains her motivation for bringing the ParadigMS initiative to the Balkan region. She highlights the importance of connecting local clinicians with internationally recognized MS experts who are both deeply knowledgeable and committed to open knowledge sharing. Watch the interview Why is international collaboration and interactive education important for improving MS care in the Balkan region? In the interview, Jelena Drulović discusses how initiatives like ParadigMS can support professional development and improve clinical practice...

Continue reading

Jelena Drulović on regional scientific collaboration as a driver of better MS care

In this short video interview, Jelena Drulović discusses the value of scientific collaboration across the Balkan region and how joint research efforts can translate directly into improved care for people with multiple sclerosis. Watch the interview Why is regional scientific collaboration particularly important in multiple sclerosis research and care? In the interview, Jelena Drulović explains how cooperation across countries enables stronger science and more effective translation of evidence into clinical decision-making. Key points discussed include: The importance of structured...

Continue reading

ParadigMS publication in NEURON(E) journal: Translating the 2024 McDonald Criteria into Clinical Practice 

Source (journal article): NEURON, Vol. 30, #3 (2025), pp. 18–22 (Dutch). In this article, Christine Lebrun-Frenay, member of the McDonald and ECTRIMS committees and co-founder of the RIS Consortium, reviews the rationale behind the 2024 revision and discusses its practical implications, particularly in asymptomatic patients transitioning from Radiologically Isolated Syndrome (RIS) to Multiple Sclerosis (MS). This publication reflects ParadigMS’ ongoing commitment to translating evolving diagnostic frameworks into clinically relevant guidance for neurologists. Key takeaways The...

Continue reading

Astrocytes and myelin – pathology and pathway

Advances in antibody testing and biomarker-driven diagnostics have reshaped the distinction between Multiple Sclerosis (MS), Neuromyelitis Optica Spectrum Disorder (NMOSD), and MOG antibody-associated disease (MOGAD). Florian Deisenhammer reviews the historical shift from considering NMO a subtype of MS to recognizing NMOSD as a distinct antibody-mediated condition, and outlines how AQP4-IgG and MOG-IgG testing – together with characteristic MRI and CSF patterns – supports more accurate diagnosis. A central message is that these diseases can overlap clinically, but differ...

Continue reading

Astrocytes and myelin – Clinical aspects: available and future treatment

This lecture explains how antibody-mediated pathology translates into clinical phenotypes and treatment strategies in Neuromyelitis Optica Spectrum Disorder (NMOSD) and Myelin Oligodendrocyte Glycoprotein Antibody Disease (MOGAD). Melinda Magyari contrasts the core targets, astrocytes (aquaporin-4) in NMOSD versus myelin/oligodendrocytes (MOG) in MOGAD, and shows how these mechanisms drive differences in relapse recovery, long-term disability, and therapeutic priorities. A major emphasis is placed on early antibody testing to avoid misdiagnosis (particularly as Multiple Sclerosis) and...

Continue reading

New insights in the 2024 McDonald criteria: imaging biomarkers shaping MS diagnosis

In this keynote lecture at the Belgian MS Symposium 2025, Pietro Maggi discussed how advanced MRI biomarkers have been integrated into the upcoming 2024 revisions of the McDonald diagnostic criteria for Multiple Sclerosis. Key Insights from the Webinar: These revisions aim to improve diagnostic precision and reduce misdiagnosis, particularly in early or atypical cases. Among the most significant updates are: Optic nerve involvement — now recognized as a fifth anatomical location for demonstrating dissemination in space (DIS), supported by MRI, visual evoked potentials (VEP), and optical...

Continue reading

FAQs

Is ParadigMS for free?

Yes, a ParadigMS subscription is free for healthcare practitioniers. 

Do subscriptions auto-renew?
Your subscription will automatically renew on yearly basis. If you cancel your plan, it will not renew at the end of your subscription cycle. 
I am a representative from industry, can I subscribe?

Free subscriptions to ParadigMS are reserved for healthcare practitioners. If you are a representative of the industry please contact us on learning@paradigms.foundation and we would advise you how to get the access to the material. 

What happens if I subscribe as a HCP if I am not?
If you subscribe as a healthcare practitioner and it is proven that you are not a healthcare practitioner, we will cancel your subscription immediately. 
I am a patient, can I subscribe?

ParadigMS is designed specifically for healthcare practitioners, with content and language tailored to their professional needs. While patients cannot subscribe directly, we encourage you to consult your healthcare provider for relevant insights and updates that may benefit you.

Why should I subscribe to ParadigMS's e-platform?

Subscribing to ParadigMS’s e-platform gives you access to up-to-date information and valuable learning materials on multiple sclerosis and NMO, along with expert insights and the latest innovations in the field. It’s an essential resource for staying informed and enhancing your knowledge in MS care.

How can I cancel my subscription?
You can cancel your subscription in your account settings. 
Can I financially support ParadigMS?

Yes, you can financially support ParadigMS! We welcome donations to help us continue our mission of advancing multiple sclerosis education and research. Your contribution directly supports the creation of educational resources, expert discussions, and innovative projects in MS care. Visit our donation page to learn more about how you can make a difference: ParadigMS Donate.